BDBM295688 Example 17 in WO2010036630::US10570125, Example 17::US11084810, Example 17 in WO2010036630::US11725004, Example 17 in WO2010036630

SMILES COCC(C)(C)c1cc(NC(=O)C(C)(C)S(=O)(=O)CC2CCOCC2)on1

InChI Key InChIKey=BDDQLSKACGXUQH-UHFFFAOYSA-N

Data  1 IC50  7 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 295688   

TargetCannabinoid receptor 2(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  30nMAssay Description:CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37° C. A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

TargetCannabinoid receptor 1(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  304nMAssay Description:CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37° C. A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  30nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetCannabinoid receptor 1(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  8.60E+3nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  30nMAssay Description:CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37° C. A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/24/2022
Entry Details
Go to US Patent

TargetCannabinoid receptor 1(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  8.60E+3nMAssay Description:CHO cells expressing human CB1 R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/24/2022
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  30nMAssay Description:CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37° C. A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 1(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataIC50: 8.60E+3nMAssay Description:CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37° C. A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent